DTS-201 (sodium)
Product Specifications
UNSPSC Description
DTS-201 sodium (CPI-0004Na) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer[1].
Target Antigen
Aminopeptidase; Peptide-Drug Conjugate (PDC)
Type
Peptides
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dts-201-sodium.html
Smiles
O=C(O[Na])CCC(NCCC(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@H]2C[C@@](C(CO)=O)(O)CC3=C2C(O)=C(C(C(C(OC)=CC=C4)=C4C5=O)=O)C5=C3O)C1)=O)=O)=O)=O)=O
Molecular Weight
1034.04
References & Citations
[1]Ravel D, et al. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008, 14(4), 1258–1265.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P10759/DTS-201-sodium-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P10759/
Clinical Information
No Development Reported
CAS Number
372491-73-1
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Human Monoclonal CTLA-4 Antibody (Antitope patent anti-CTLA4) [Janelia Fluor 585]](https://cdn.genprice.uk/genprice/genprice4.png)
NBP3-28818JF585 0.1 mL
Human Monoclonal CTLA-4 Antibody (Antitope patent anti-CTLA4) [Janelia Fluor 585]
Ask
View Details 